A whistleblower tells the Associated Press that the U.S. Drug Enforcement Administration (DEA) allowed fentanyl pills to reach streets in New Mexico, raising concerns about whether people were put at risk during an undercover effort. The Independent and India Today report that the whistleblower claims the approach was intended to build larger cases, rather than immediately stopping the flow of the drugs. According to the reports, the whistleblower warns that the decision had consequences, including the possibility of deaths. The claims focus on DEA actions in New Mexico and suggest the agency permitted distribution to gather evidence against traffickers. The outlets describe the allegations as being based on information provided to AP, with the central dispute centered on whether investigative tactics involved allowing fentanyl to circulate. The reporting indicates the matter has prompted scrutiny of DEA procedures and oversight, particularly regarding the balance between building prosecutions and preventing harm to the public.